Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre, Open-label, Phase I/II Study Investigating the Safety, Tolerability, and Preliminary Efficacy of 225Ac-SSO110 in Participants With Extensive Stage Small Cell Lung Cancer (ES-SCLC) or Merkel Cell Carcinoma (MCC) Receiving Standard of Care (SoC)

Next Previous
Trial Profile

A Multicentre, Open-label, Phase I/II Study Investigating the Safety, Tolerability, and Preliminary Efficacy of 225Ac-SSO110 in Participants With Extensive Stage Small Cell Lung Cancer (ES-SCLC) or Merkel Cell Carcinoma (MCC) Receiving Standard of Care (SoC)

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 09 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Actinium-225-satoreotide-Ariceum-Therapeutics (Primary) ; Atezolizumab; Avelumab; Durvalumab; Pembrolizumab; Retifanlimab
  • Indications Merkel cell carcinoma; Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SANTANA-225
  • Sponsors Ariceum Therapeutics

Most Recent Events

  • 05 Feb 2026 Status changed from recruiting to discontinued. Reason the study was stopped: Study terminated due to strategic business decisions.
  • 11 Nov 2025 According to an Ariceum Therapeutics media release, first patient has been dosed in this study. Initial safety data expected in 2026.
  • 09 Oct 2025 According to an Ariceum Therapeutics media release, the initial safety data from SANTANA-225 expected in 2026 and preliminary efficacy data in 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top